UCB4594 / UCB, Cancer Research UK - LARVOL DELTA

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer (clinicaltrials.gov) - P1/2 | N=167 | Recruiting | Sponsor: Cancer Research UK | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Breast Cancer • Cervical Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • Uterine Cancer

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer (clinicaltrials.gov) - P1/2 | N=167 | Not yet recruiting | Sponsor: Cancer Research UK

Combination therapy • Metastases • New P1/2 trial • Breast Cancer • Cervical Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • Uterine Cancer

Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594 (ESMO-IO 2023) - "Across 20 human tumours, UCB4594 IgG1 led to 1.5-fold higher tumour cell death than the isotype control in 9 tumours, seen at 24h/72h post-treatment. Conclusions These findings support the development of UCB4594 as a novel cancer immunotherapy for application in several solid tumour indications."

Oncology • Solid Tumor • HLA-G

Cancer Research UK reach agreement with UCB (PharmaTimes) - "Cancer Research UK and UCB have announced a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The partnership will concentrate on the development of two investigational antibody candidates – UCB6114 and UCB4594....As part of the collaboration, Cancer Research UK’s Centre for Drug Development will appoint the chief clinical and scientific investigators, and will oversee the design, preparation, sponsorship and delivery of phase 1/2 clinical trials for both candidates."

Licensing / partnership • New P1/2 trial • Oncology